Dramatic Response to Cabozantinib in a Patient with Refractory Hepatocellular Carcinoma with c-MET Amplification

作     者：Yun Beom Sang Gwangil Kim Sohyun Hwang Haeyoun Kang Hong Jae Chon 

作者机构：Department of Medical OncologyCHA Bundang Medical CenterCHA University School of MedicineSeongnam-siGyeonggi-doKorea Department of PathologyCHA Bundang Medical CenterCHA University School of MedicineSeongnam-siGyeo-nggi-doKorea CHA Future Medicine Research InstituteCHA Bundang Medical CenterSeongnam-siGyeonggi-doKorea 

出 版 物：《Journal of Clinical and Translational Hepatology》 (临床与转化肝病杂志（英文版）)

年 卷 期：2023年第11卷第3期

页      面：747-750页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：the National Research Founda-tion of Korea(NRF)grant funded by the Korea government(MSIT)(NRF-2020R1C1C1010722 to HJC) 

主　　题：Hepatocellular carcinoma c-MET amplification Cabozantinib Dra-matic response Next-generation sequencing 

摘      要：We report a case of a patient with c-MET amplified hepato-cellular carcinoma (HCC) who had a dramatic response to cabozantinib despite being refractory to four previous lines of systemic therapy. The patient had previously received re-gorafenib plus nivolumab as first-line treatment, lenvatinib as second-line, sorafenib as third-line, and ipilimumab plus nivolumab as fourth-line treatment in sequence. However, all regimens showed early progression within 2 months. The pa-tient’s HCC was well-controlled, with a partial response (PR) of over 9 months after beginning cabozantinib treatment. Although there were mild adverse events such as diarrhea and elevated liver enzymes, they were tolerable. Next-gen-eration sequencing (NGS) of the patient’s previous surgical specimen indicated amplification of c-MET genes. Although it is well known that cabozantinib has excellent effectiveness for inhibiting c-MET at the preclinical level, to the best of our knowledge this is the first case of dramatic response to cabozantinib in a patient with advanced HCC with c-MET am-plification.